Market Size in 2021 | Market Forecast in 2028 | CAGR (in %) | Base Year |
---|---|---|---|
USD 9.1 Billion | USD 13.4 Billion | 6.7% | 2021 |
The global needle-free diabetes care market size was worth USD 9.1 billion in 2021 and is estimated to grow to USD 13.4 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.7% over the forecast period. The report analyzes the needle-free diabetes care market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the needle-free diabetes care market.
Diabetes is a collection of metabolic illnesses in which a person's blood sugar levels are elevated due to insufficient insulin production, improper cell response to insulin, or both or neither of these factors. To diagnose a patient, blood samples are typically drawn from them. This technique can result in needle-stick injuries, leading to several infections and suffering. People are using non-invasive, needle-free diabetic products as a result. During the projected period, an expanding patient population with diabetes and a rising prevalence of type 1 diabetes are expected to propel market expansion.
Traditionally, patients with type 1 diabetes who need frequent glucose testing use needles, which raises the risk of infection and discomfort for people. The use of needle-free equipment reduces delivery discomfort and infection risk.
Therefore, it is anticipated that there will be an increase in demand for these devices during the forecast period. Additionally, the industry has been driven by rising demand and technological developments in pain-free drug transportation and self-administration. However, the high cost of the facility and worries about technical difficulties are the factors anticipated to restrain the market's expansion for needle-free diabetes care.
In a best-case scenario, it may be assumed that the COVID-19 epidemic has positively affected the adoption of needle-free injection systems. The COVID-19 pandemic has favorably impacted the global needle-free diabetes care market. It has brought attention to the necessity for self-injectable devices and mass vaccinations since the pandemic outbreak began in December 2019. To develop a needle-free injection system for the disease, as the number of cases has increased across regions, most hand-free injection system players have invested in R&D and have formed partnerships & agreements with other business and governmental entities.
Increasing diabetes prevalence drives global needle-free diabetes care market growth
Diabetes is anticipated to be the sixth most significant cause of death by 2030, according to the WHO. Stress, sedentary habits, poor diets, and obesity are the main diabetes risk factors. Physiological changes brought on by aging play a sizable role in diabetes risk. For instance, the International Diabetes Federation claims that the prevalence of diabetes rises with age. Therefore, those over 65 years old are thought to have the highest estimated risk of diabetes. Adults aged 20 to 24 had the lowest prevalence of diabetes (2.2% in 2021). Diabetes prevalence is at 24.0% among persons aged 75 to 79 as of 2021 and is expected to rise to 24.7% by 2045. According to these figures, most diabetes will significantly grow over the next 25 years in nations with substantial geriatric populations. Therefore, it is anticipated that the need for needles less diabetes management solutions will be driven by the growing elderly population and the population's increased exposure to leading risk factors.
Report Attributes | Report Details |
---|---|
Report Name | Needle-Free Diabetes Care Market Research Report |
Market Size in 2021 | USD 9.1 Billion |
Market Forecast in 2028 | USD 13.4 Billion |
Growth Rate | CAGR of 6.7% |
Number of Pages | 210 |
Key Companies Covered | European Pharma Group, Medical International Technology Inc., Antares Pharma Inc., Zogenix Inc., 3M Company, Valeritas Inc., Endo International plc., INJEX Pharma AG, and Bioject Medical Technologies Inc |
Segments Covered | By Devices Types, By Treatment, By Application, By End Users and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2021 |
Historical Year | 2016 to 2020 |
Forecast Year | 2021 - 2028 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
More people using traditional diabetes management tools restraints the market demand
Patients still favor conventional diabetes management strategies in various geographical areas. With their low cost and lack of information about linked devices and apps, many patients reject advanced platforms in favor of traditional blood glucose readers, glucose strips, insulin injections, prefilled syringes, and medication therapy. The limited knowledge for managing diabetes in various nations has also impacted the acceptance of cutting-edge technologies. The use of needle-less diabetes management has been negatively affected in Asia, the Middle East, and Africa due to low awareness, a lack of educated staff, and unfavorable/minimal reimbursements. The market expansion in China and India is also being constrained by the reliance on complementary traditional diabetes control techniques like herbal medications.
The global needle-free diabetes care market is segregated based on device types, treatment, application, end users, and region.
By treatment, the market is divided into oral insulin, inhaled insulin, insulin patch, and others. With its outstanding efficiency, the insulin patch segment was shown to have the fastest expanding market share in 2021. The significant growth rate can be ascribed to elements like the rising incidence of diabetes and growing public knowledge of sophisticated patch pumps. People with type 1 diabetes prefer insulin patch pumps since they do not need to carry an insulin infusion set. Patch pumps are chosen by older and working individuals because of their greater convenience.
Patch pumps are generally smaller, more discrete, and easier to use than conventional insulin pumps. These pumps are also more affordable than traditional insulin delivery methods, which boosts demand. Patch pumps use an adhesive coating to bond to the skin and need minimal supervision. These pumps typically come with a blood glucose monitoring system or a continuous glucose monitor.
Based on application, the market is divided into insulin delivery and others. The global needle-free diabetes care market's most popular application area in 2021 was insulin delivery. The enormous population with diabetes drives the demand for insulin delivery devices. Additionally, the widespread use of recently introduced inventive pen devices and portable pumps is being aided by the rising demand for sophisticated insulin delivery systems, which is anticipated to accelerate market expansion.
Some of the main competitors dominating the global needle-free diabetes care market include - European Pharma Group, Medical International Technology Inc., Antares Pharma Inc., Zogenix Inc., 3M Company, Valeritas Inc., Endo International plc., INJEX Pharma AG, and Bioject Medical Technologies Inc.
Growing prevalence of diabetics likely to help North America dominate the global market
North America held a monopoly on the global needle-free diabetes care market in 2021. The significant market growth in North America is mainly due to the increased number of diabetics and the availability of technologically improved equipment. By 2025, there are likely to be 5 million Canadians living with diabetes, according to the Canadian Diabetes Association. Therefore, it is anticipated that the vast patient population suffering from diabetes and its rising prevalence will spur growth in this area.
The region's dominance in the international arena has been aided by a high level of awareness regarding the potential advantages of needle-free drug delivery devices. Additionally, the market is expanding due to the availability of highly developed healthcare facilities and significant R&D spending by government agencies and pharmaceutical corporations to treat diabetes.
By Devices Types
By Treatment
By Application
By End Users
By Region
FrequentlyAsked Questions
One of the key drivers fueling the expansion of the needle-free diabetes treatment market is the development of transdermal patches, which measure blood sugar levels via the skin without extracting blood.
According to the report, the global needle-free diabetes care market was worth about 9.1 (USD billion) in 2021 and is predicted to grow to around 13.4 (USD billion) by 2028, along with a compound annual growth rate (CAGR) of approximately 6.7%.
North America now monopolizes the needle-free diabetes treatment industry due to its vast diabetic population, changing lifestyle, rising healthcare costs, and adaptive population.
Some of the main competitors dominating the global needle-free diabetes care market include - European Pharma Group, Medical International Technology Inc., Antares Pharma Inc., Zogenix Inc., 3M Company, Valeritas Inc., Endo International plc., INJEX Pharma AG, and Bioject Medical Technologies Inc.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed